Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at cryptodailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. CryptoDailyPress.com is also looking into these tickers COIN, CIFR, BTBT, RIOT, IBLC, HIVE, BITQ, BKCH, BBKCF..
Recent ABT Stock Price: $109.95
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
Matt Miksic analyst at Barclays reiterates coverage on Abbott Labs (ABT) stock in the energy sector with a Buy rating and has set ABT's stock price target at $ 125.
TipRanks.com reports that Abbott Labs currently has 11 analysts offering 12-month price targets on ABT and the consensus is a Moderate Buy rating with an average stock price target of $123.82. The most recent ABT stock price we have is $109.95 and we are not making any ABT forecasts at this time.
In addition, TradingView issued a Neutral rating for ABT over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ABT, please click here >>
Iovance Biotherapeutics, IOVA
Recent IOVA Stock Price: $8.16
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
Joseph Catanzaro analyst at Piper Sandler reiterates coverage on Iovance Biotherapeutics (IOVA) stock in the energy sector with a Buy rating and has set IOVA's stock price target at $ 14.
TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets on IOVA and the consensus is a Strong Buy rating with an average stock price target of $22.78. The most recent IOVA stock price we have is $8.16 and we are not making any IOVA forecasts at this time.
In addition, TradingView issued a Buy rating for IOVA over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IOVA, please click here >>
Rain Therapeutics, RAIN
Recent RAIN Stock Price: $10.02
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
Yigal Nochomovitz analyst at Citigroup reiterates coverage on Rain Therapeutics (RAIN) stock in the energy sector with a Buy rating and has set RAIN's stock price target at $ 29.
TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets on RAIN and the consensus is a Strong Buy rating with an average stock price target of $18.14. The most recent RAIN stock price we have is $10.02 and we are not making any RAIN forecasts at this time.
In addition, TradingView issued a Buy rating for RAIN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RAIN, please click here >>
The editors at cryptodailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Click here to join thousands of investors who are interested in crypto currency, Bitcoin, blockchain technology and more.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.